Abstract
Clinical outcomes for patients with rare subtypes of advanced/relapsed gynaecological cancers including clear cell, carcinosarcomas and cervical cancer, are exceptionally poor with limited effective treatment options. Loss of function mutations in the tumour suppressor gene ARID1A have been reported in rarer gynaecological cancers including clear cell subtypes, although the clinical significance of ARID1A alterations remains unclear. Preclinical data demonstrate cancers with ARID1A gene defects (ARID1A-loss) display increased sensitivity to ATR inhibitor therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
